Search Results
Your search for ,ITS matches 8694 pages
Showing 7351 - 7400Mesenchymal Stem Cells With Oncolytic HSV Variants Promising in Glioblastoma Multiforme
Although oncolytic herpes simplex virus (HSV) has been found to be safe in clinical trials in malignant glioblastoma multiforme, its efficacy is limited by insufficient viral spread after tumor resection. In a study reported in the Journal of the National Cancer Institute, Duebgen and colleagues...
FDA Commissioner Margaret A. Hamburg’s Statement on the Surgeon General’s Call to Action to Prevent Skin Cancer
Each year, thousands of Americans are diagnosed with some form of skin cancer. The Surgeon General’s Call to Action to prevent skin cancer is important especially during these hot summer months when many of us spend extra time in the sun. Over the last few years, the FDA has taken a number of...
Surgeon General Call to Action to Prevent Skin Cancer
On July 29, 2014, the Surgeon General issued a Call to Action urging immediate action steps to prevent skin cancer. The report encourages increased awareness of the disease and calls for immediate and collaborative actions to reduce its risk. Nearly 5 million people are treated for skin cancer in...
Cancer Survivor and Patient Advocate Michael S. Katz, MBA, Has Helped Alter the Standard of Care for Myeloma Survivors
Michael S. Katz, MBA, has lived longer than any of his doctors thought he would. A two-time cancer survivor, Mr. Katz was diagnosed, first with multiple myeloma in 1990 and then with colorectal cancer in 2008, and has spent the past 2 decades tirelessly advocating for patients with cancer. The...
Focus on the Florida Society of Clinical Oncology
The Florida Society of Clinical Oncology (FLASCO) was founded in 1977, just 13 years after the founding of ASCO. Today, the Society has had such an impact on the practices of medical, radiation, surgical, gynecologic, and pediatric oncologists throughout the state, membership has risen to over...
How Technology Is Helping Bring Health Care to Patients
The term “telemedicine,” which is sometimes used interchangeably with “telehealth” and “m-health” (for mobile health) and is now collectively called “connected health,” involves the use of information and communications technology to connect patients with their providers through a variety of...
AACR Issues Statement to Applaud FDA’s Actions
In a statement released earlier this month, the American Association for Cancer Research (AACR) applauded the U.S. Food and Drug Administration (FDA) for issuing its final guidance on “In Vitro Companion Diagnostic Devices” and proposing its “Framework for Regulatory Oversight of Laboratory...
FDA Takes Steps to Help Ensure the Reliability of Certain Diagnostic Tests
The U.S. Food and Drug Administration (FDA) recently took important steps to ensure that certain tests used by health-care professionals to help diagnose and treat patients provide accurate, consistent, and reliable results. First, the FDA is issuing a final guidance on the development, review, and ...
Book Excerpt: Family
I've witnessed incredible courage and zest for life among so many patients from so many walks of life—individuals committed to helping others in spite of their own adversity. Forty years ago, when survival for patients with multiple myeloma was a matter of months, I knew that every person I sat...
Patrick Soon-Shiong, MD, to Lead Providence Health Cancer Services and Bioinformatics
Providence Health & Services has announced that Patrick Soon-Shiong, MD, will serve as the health-care system’s new Global Director for Cancer Services and Bioinformatics. In this role, Dr. Soon-Shiong will work closely with oncology clinicians and researchers across the five-state Providence...
Red Clover
The use of dietary supplements by patients with cancer has increased significantly over the past 2 decades despite insufficient evidence of safety and effectiveness. Finding reliable sources of information about dietary supplements can be daunting. Patients typically rely on family, friends, and...
Lung Cancer Alliance Commends National Cancer Institute for Its New Scientific Framework for Small Cell Lung Cancer
The National Cancer Institute (NCI) recently presented to Congress a scientific framework that lays out important steps needed to make advances in small cell lung cancer. The report, entitled “Scientific Framework for Small Cell Lung Cancer (SCLC)” was mandated by the Recalcitrant Cancer Research...
Using Patient-Reported Outcome Measures in Palliative Care Clinical Practice
Incorporating patient-reported outcomes into the palliative care clinical setting can improve patients’ symptom management, quality of life, and overall communication with their oncologists, according to Ethan Basch, MD. Dr. Basch is Director of the Cancer Outcomes Research Program and Associate...
IPOS Celebrates 30th Anniversary at World Congress in Lisbon
The International Psycho-Oncology Society (IPOS) will be celebrating its 30th anniversary at the 16th World Congress of Psycho-Oncology and Psychosocial Academy being held in Lisbon, Portugal from October 20-24, 2014. The Congress will feature a plenary session with nine past presidents, whose...
New TV Ads, New Stories for CDC’s Tips From Former Smokers Campaign
The Centers for Disease Control and Prevention (CDC) continues its national tobacco education campaign—Tips From Former Smokers—with hard-hitting, new ads that show the harms caused by smoking. Beginning last month, ads will appear for a total of 9 weeks across television, radio, billboards, and...
A Book of Solid Advice and ‘Silver Linings’ for Patients With Breast Cancer
Title: The Silver Lining: A Supportive & Insightful Guide to Breast CancerEditors: Hollye Jacobs, RN, MS, MSWPublishing Platform: CreateSpace Publication information: Simon & Schuster, published March 2014. Available at Amazon, Barnes and Noble, Indiebound, and other local bookstores....
Discussing Sexual Health Issues With Female Cancer Survivors
Advances in cancer treatment have led to increasing numbers of long-term survivors, bringing greater attention to the needs of this growing population. Female cancer patients often experience difficult adjustments related to sexual health and intimacy. To better understand the complexity of this...
Pioneering Medical Oncologist Remembers a Time Before the Subspecialty Was Created
While the first written record of cancer dates back to ancient Egypt, the history of modern oncology is fairly short, dating back only slightly more than half a century. Clinical trials in the early days of the National Cancer Institute (NCI) and the emerging cooperative groups were led by a...
Lynda Chin, MD, Named a Recipient of the Chancellor’s Health Fellowship by The University of Texas Systems
The University of Texas System named MD Anderson scientist Lynda Chin, MD, as a recipient of the System’s Chancellor’s Health Fellowship. Dr. Chin, Chair of the Department of Genomic Medicine, was recognized for development of a patient-centric oncology care delivery system initiated in late 2012....
Prominent Immunotherapy Researcher Sees Success Beyond the Challenges
Activating the immune system for therapeutic benefit in cancer patients has long been a goal in the scientific community. After decades of disappointment, this intriguing approach has come to the forefront of cancer research, showing promising results in several malignancies. To keep abreast of...
Life: Magnified Exhibit Continues to Heighten Public Awareness About Science, On Display and Online
Life: Magnified is an exhibit of scientific images showing cells and other scenes of life magnified by as much as 50,000 times. The exhibit is on display at Washington Dulles International Airport’s Gateway Gallery from June through November 2014. A Web companion is available through NIH here...
Getting Results: How Oncologists and Pathologists Can Work Together to Facilitate Molecular Testing
Advances in molecular testing mean that highly specific information can be detailed about the molecular characteristics of a patient’s tumor, as well as indications of potential responsiveness to targeted therapy. But getting those detailed results from the pathologists can be a challenge to many...
Active Surveillance in Low-Risk Prostate Cancer: When Will We Pay It More Than Just Lip Service?
Active surveillance is well established as an appropriate management option for men with low-risk prostate cancer and particularly for those over 65 years of age. Its legitimacy is now enshrined within National Comprehensive Cancer Network guidelines, in the American Society for Radiation Oncology...
FDA Approval of Ceritinib for the Treatment of ALK-Positive Non–Small Cell Lung Cancer
INSIDE THE BLACK BOX is an occasional column providing insight into the U.S. Food and Drug Administration (FDA) and its policies and procedures. In this installment, FDA oncologists Sean Khozin, MD, MPH, and Dikran Kazandjian, MD, discuss anaplastic lymphoma kinase (ALK)-positive non–small cell...
ASCO Launches Online Resource to Help Oncologists Understand the Impact of the Affordable Care Act
This year, major provisions of the Patient Protection and Affordable Care Act of 2010 are being implemented, with far-reaching impacts on health-care providers and patients. In addition to implementing requirements under the new law, oncology practices are treating considerably more patients with...
Proposed 2015 Medicare Physician Fee Schedule and Hospital Outpatient Prospective Payment System Rules Released
On July 3, 2014, the Centers for Medicare & Medicaid Services (CMS) released its proposed rules for the Medicare Physician Fee Schedule and the Hospital Outpatient Prospective Payment System for 2015. The Medicare Physician Fee Schedule rule, which is titled “Medicare Program: Revisions to...
Our First Charge: Fostering the Next Generation of Oncologists and Cancer Researchers
Gary H. Lyman, MD, MPH, FASCO, is Co-Director of the Hutchinson Institute for Cancer Outcomes Research, a Full Member of the Divisions of Public Health Sciences and Clinical Research at the Fred Hutchinson Cancer Research Center, and Professor of Medicine, Public Health, and Pharmacy at the...
More Collaboration Needed Between Oncologists and Primary Care Physicians
One of the most important cancer survivorship issues is the transition from oncologist to the primary care setting. With a growing population of cancer survivors, patients need to feel secure about their primary care provider having the tools to address their special needs. To shed light on this...
Fred Hutchinson Cancer Research Center Researcher Veena Shankaran, MD, to Receive ‘40 Under 40’ Award
The Puget Sound Business Journal (PSBJ) has recognized Veena Shankaran, MD, a Medical Oncologist and Health Economist at Fred Hutchinson Cancer Research Center, as one of 40 individuals under age 40 who have demonstrated extraordinary leadership within their field. Dr. Shankaran will accept the...
Patience Remains a Virtue: The Ongoing Quest to Optimize Adjuvant Endocrine Therapy in Breast Cancer
The most recent ASCO Clinical Practice Guideline update—summarized in this issue of The ASCO Post—represents the latest chapter in the ongoing evolution of adjuvant endocrine therapy for hormone-sensitive breast cancer.1 Rather than including a comprehensive review of the 2010 guidelines, this...
Adjuvant Endocrine Therapy for Hormone Receptor–Positive Breast Cancer: ASCO Clinical Practice Guideline Focused Update
ASCO has released a focused update of its clinical practice guideline on adjuvant endocrine therapy in women with hormone receptor–positive breast cancer.1 The focused update, formulated by Harold J. Burstein, MD, PhD, of Dana-Farber Cancer Institute, Boston, and colleagues in the ASCO Update...
FDA Grants Bevacizumab Priority Review for Recurrent Platinum-Resistant Ovarian Cancer
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application and granted Priority Review for bevacizumab (Avastin) plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer. “The majority of women with ovarian...
FDA Grants Bevacizumab Priority Review for Certain Types of Cervical Cancer
The U.S. Food and Drug Administration (FDA) has accepted Genentech’s supplemental Biologics License Application and granted Priority Review for bevacizumab (Avastin) plus chemotherapy in the treatment of women with persistent, recurrent, or metastatic cervical cancer. The designation of Priority...
Study Finds New Genetic Risk Markers in Pancreatic Cancer
A large DNA analysis of people with and without pancreatic cancer has identified several new genetic markers that signal increased risk of developing the disease, report scientists from Dana-Farber Cancer Institute and other institutions worldwide. The markers are variations in the inherited DNA...
The Evolving Role of Surgery in Germ Cell Tumors
Over the past several decades, the role of postchemotherapy surgery for advanced testicular cancer has evolved with regard to patient selection, surgical planning, lymph node dissection, and surgical technique. To add clarity to this complex clinical setting, The ASCO Post recently spoke with...
Enzalutamide and the Landscape of Castration-Resistant Prostate Cancer: Integrating New Indications With Existing Agents
The androgen receptor axis is a validated target for the treatment of castration-resistant prostate cancer. Several perturbations in this pathway are postulated to lead to androgen-independent growth, including androgen receptor mutation and amplification as well as the autocrine production of...
EGFR as a Therapeutic Target for Gastroesophageal Cancer—or Is It Really?
The epidermal growth factor receptor (EGFR) gene is often amplified and its protein overexpressed in upper gastrointestinal cancers—and overexpression has prognostic value. With the advent of monoclonal antibodies and tyrosine kinase inhibitors against EGFR, we have witnessed a rash of randomized...
NEPA for Chemotherapy-Induced Nausea and Vomiting: Key Endpoints and Additional Analyses Show Strong Efficacy
For the prevention of chemotherapy-induced nausea and vomiting, NEPA, a novel combination of a neurokinin-1 (NK1) receptor antagonist and the 5-HT3 receptor antagonist palonosetron (Aloxi), has been studied in three pivotal trials that were recently published in the Annals of Oncology.1-3 Further...
MASCC Awards Honorary Lifetime Membership
The Multinational Association for Supportive Care in Cancer (MASCC) has awarded Honorary Lifetime Membership status to Hans-Jürg Senn, MD, based on his commitment, vision, and extraordinary service to the Society and its publication Supportive Care in Cancer, according to Society News, the MASCC...
Mucositis Remains a Challenge in Head and Neck Cancer
Chemoradiotherapy for head and neck cancer requires intensive supportive care by a knowledgeable and proactive multidisciplinary team, according to Avraham Eisbruch, MD, Professor of Radiation Oncology at the University of Michigan, Ann Arbor. “Aggressive chemoradiotherapy has improved the cure...
Mixed Results for Targeting MET in Non–Small Cell Lung Cancer
Two different abstracts explored the potential for MET as a therapeutic target in patients with metastatic non–small cell lung cancer (NSCLC), with different results. A phase III study found that onartuzumab, an antibody that targets the MET receptor, combined with erlotinib (Tarceva) was not as...
Who Will Care for Patients With Cancer?
The workforce numbers show a disturbing trend. According to a recent study by ASCO, by 2025, overall demand for oncology services is projected to grow by 40%, but physician supply is predicted to increase by only 25%, generating a shortage of 2,258 oncologists providing full-time equivalent...
Does the United States Have the Best Health-Care System in the World?
Many concerns were raised and dire speculations predicted during the further implementation of the Affordable Care Act this year. So far, the trickling news is good: An estimated total of 20 million people gained coverage under the new law as of May 1,1 about 6 million enrolled in the law’s...
Recent FDA Drug Approvals Foster Growing Treatment Armamentarium for Chronic Lymphocytic Leukemia and Rare B-Cell Lymphomas
Recent approvals announced by the U.S. Food and Drug Administration (FDA) have led to increased treatment options for managing several difficult-to-treat hematologic B-cell cancers. The newly approved drugs and/or their indications include the oral PI3K delta inhibitor idelalisib (Zydelig) for the...
Jesse L. Steinfeld, MD, Past Surgeon General, ASCO President, Dies at 87
The 1964 Surgeon General’s Report on Smoking and Health started a culture change in the way Americans viewed tobacco and their health, and has saved countless million of lives. But the 1964 Report remained scientifically ambiguous on certain vital issues, such as the effect smoking had on the...
First Prospective Study of Rare Lymphoma Shows Promising but Inconclusive Results With DA-EPOCH-R
Presenting “the first prospective study” of mediastinal gray zone lymphoma, researchers from the National Cancer Institute reported that DA-EPOCH-R (infusional dose-adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine, prednisone, and rituximab (Rituxan) and filgrastim (Neupogen)...
Dysregulated Cell-Cycle Progression and Akt Hyperactivation in Cancer
Akt plays important roles in cell proliferation, survival, and metabolism. Akt hyperactivation contributes to tumorigenesis and is associated with poor prognosis and resistance to chemotherapy and radiotherapy. It is known that activation of Akt results from phosphorylation at S473 and T308, but it ...
Fusion Protein Improves Dendritic Cell Penetration, Raising Prospect of Efficient Cancer Vaccine
Immunotherapy with dendritic cells in combination with cytotoxic chemotherapy may eliminate minimal disease burden by generating cytotoxic T lymphocytes (CTLs). Improving the cytosolic bioavailability of tumor-specific antigens to improve access to HLA class I molecules would result in better...
BET Bromodomain Inhibition Highly Active in Castration-Resistant Prostate Cancer
Progression to castration-resistant prostate cancer after androgen ablation therapy is primarily due to deregulated androgen receptor signaling. Treatment with agents that target such signaling, such as abiraterone (Zytiga) and enzalutamide (Xtandi), has been successful. However, durable response...
Gynecologic Cancer Care: Collaboration With Resource-Challenged Ethiopia
Over the past 40 years, largely because of universal Pap screening, cervical cancer deaths have been drastically reduced in the United States and other wealthy industrialized countries. However, cervical cancer is still a leading cause of cancer death among women in resource-challenged areas of the ...
